FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Caroline Springer

Research Profile

Chemicals & Drugs

Procedures

Living Beings

Anatomy

Disorders

Concepts & Ideas

Structure-Activity Relationship

Co-author Network

Publications

TOP 3
Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Jean-Francois Pons; Lawrence Davies; Richard Marais; Delphine Ménard; Bart M J M Suijkerbuijk; Steven Whittaker; Alfonso Zambon; Caroline J Springer
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Alfonso Zambon; Richard Marais; Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Caroline J Springer
BRAF as a therapeutic target: a patent review (2006 - 2012).
Jonathan C Welti; David Robertson; Kevin Sharpe; Julie Soffe; Caroline J Springer; Antoinette van Weverwijk; Demelza Bird; Janine T Erler; Shane Foo; Julie Foster; Sophia Frentzas; Morgane Gourlaouen; Stephen J Mather; Roberto Pili; Thomas Powles; Natasha Preece; Andrew R Reynolds
Contrasting effects of sunitinib within in vivo models of metastasis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Caroline Springer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Jean-Francois Pons; Lawrence Davies; Richard Marais; Delphine Ménard; Bart M J M Suijkerbuijk; Steven Whittaker; Alfonso Zambon; Caroline J Springer
Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Bioorganic & medicinal chemistry 2013;21(5):1284-304.
2013: Alfonso Zambon; Richard Marais; Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Caroline J Springer
BRAF as a therapeutic target: a patent review (2006 - 2012).
Expert opinion on therapeutic patents 2013;23(2):155-64.
2012: Jonathan C Welti; David Robertson; Kevin Sharpe; Julie Soffe; Caroline J Springer; Antoinette van Weverwijk; Demelza Bird; Janine T Erler; Shane Foo; Julie Foster; Sophia Frentzas; Morgane Gourlaouen; Stephen J Mather; Roberto Pili; Thomas Powles; Natasha Preece; Andrew R Reynolds
Contrasting effects of sunitinib within in vivo models of metastasis.
Angiogenesis 2012;15(4):623-41.
2011: Yann Jamin; Martin O Leach; Thomas R Eykyn; Evon S C Poon; Simon P Robinson; Lynette Smyth; Caroline J Springer; Geoffrey S Payne
Noninvasive detection of carboxypeptidase G2 activity in vivo.
NMR in biomedicine 2011;24(4):343-50.
2010: Steven Whittaker; Delphine Ménard; Ruth Kirk; Lesley M Ogilvie; Douglas Hedley; Alfonso Zambon; Filipa Lopes; Natasha Preece; Helen Anuradha Manne; Sareena Rana; Maryou B K Lambros; Jorge S Reis-Filho; Richard Marais; Caroline J Springer
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.
Cancer research 2010;70(20):8036-44.
2010: Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Bart M J M Suijkerbuijk; Delphine Ménard; Alfonso Zambon; Arnaud Nourry; Lawrence Davies; Helen Anuradha Manne; Frank Friedlos; Lesley M Ogilvie; Douglas Hedley; Andrew K Takle; David M Wilson; Jean-Francois Pons; Tom Coulter; Ruth Kirk; Neus Cantarino; Steven Whittaker; Richard Marais; Caroline J Springer
Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Bioorganic & medicinal chemistry 2010;18(18):6934-52.
2010: Alfonso Zambon; Delphine Ménard; Bart M J M Suijkerbuijk; Ion Niculescu-Duvaz; Steven Whittaker; Dan Niculescu-Duvaz; Arnaud Nourry; Lawrence Davies; Helen Anuradha Manne; Filipa Lopes; Natasha Preece; Douglas Hedley; Lesley M Ogilvie; Ruth Kirk; Richard Marais; Caroline J Springer
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Journal of medicinal chemistry 2010;53(15):5639-55.
2010: Bart M J M Suijkerbuijk; Ion Niculescu-Duvaz; Catherine Gaulon; Harmen P Dijkstra; Dan Niculescu-Duvaz; Delphine Ménard; Alfonso Zambon; Arnaud Nourry; Lawrence Davies; Helen Anuradha Manne; Frank Friedlos; Lesley M Ogilvie; Douglas Hedley; Filipa Lopes; Natasha P U Preece; Javier Moreno-Farre; Florence I Raynaud; Ruth Kirk; Steven Whittaker; Richard Marais; Caroline J Springer
Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Journal of medicinal chemistry 2010;53(7):2741-56.
2010: Arnaud Nourry; Alfonso Zambon; Lawrence Davies; Ion Niculescu-Duvaz; Harmen P Dijkstra; Delphine Ménard; Catherine Gaulon; Dan Niculescu-Duvaz; Bart M J M Suijkerbuijk; Frank Friedlos; Helen Anuradha Manne; Ruth Kirk; Steven Whittaker; Richard Marais; Caroline J Springer
BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.
Journal of medicinal chemistry 2010;53(5):1964-78.
2010: Nathalie Dhomen; Silvy da Rocha Dias; Robert Hayward; Lesley Ogilvie; Douglas Hedley; Veronique Delmas; Afshan McCarthy; Deborah Henderson; Caroline J Springer; Catrin Pritchard; Lionel Larue; Richard Marais
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethality.
Pigment cell & melanoma research 2010;23(1):112-20.
2010: Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Cell 2010;140(2):209-21.
2009: Yann Jamin; Cristina Gabellieri; Lynette Smyth; Steven Reynolds; Simon P Robinson; Caroline J Springer; Martin Leach; Geoffrey S Payne; Thomas R Eykyn
Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2009;62(5):1300-4.
2009: Delphine Ménard; Ion Niculescu-Duvaz; Harmen P Dijkstra; Dan Niculescu-Duvaz; Bart M J M Suijkerbuijk; Alfonso Zambon; Arnaud Nourry; Esteban Roman; Lawrence Davies; Helen Anuradha Manne; Frank Friedlos; Ruth Kirk; Steven Whittaker; Adrian Gill; Richard Taylor; Richard Marais; Caroline J Springer
Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.
Journal of medicinal chemistry 2009;52(13):3881-91.
2009: Laura Mancini; Lawrence Davies; Frank Friedlos; Maria Falck-Miniotis; Andrzej S Dzik-Jurasz; Caroline J Springer; Martin Leach; Geoffrey S Payne
A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
NMR in biomedicine 2009;22(5):561-6.
2009: Dan Niculescu-Duvaz; Catherine Gaulon; Harmen P Dijkstra; Ion Niculescu-Duvaz; Alfonso Zambon; Delphine Ménard; Bart M J M Suijkerbuijk; Arnaud Nourry; Lawrence Davies; Helen Anuradha Manne; Frank Friedlos; Lesley M Ogilvie; Douglas Hedley; Steven Whittaker; Ruth Kirk; Adrian Gill; Richard Taylor; Florence I Raynaud; Javier Moreno-Farre; Richard Marais; Caroline J Springer
Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).
Journal of medicinal chemistry 2009;52(8):2255-64.
2008: Dan Niculescu-Duvaz; Jayne Getaz; Caroline J Springer
Long functionalized poly(ethylene glycol)s of defined molecular weight: synthesis and application in solid-phase synthesis of conjugates.
Bioconjugate chemistry 2008;19(4):973-81.
2007: Silke Schepelmann; Lesley M Ogilvie; Douglas Hedley; Frank Friedlos; Janet Martin; Ian Scanlon; Ping Chen; Richard Marais; Caroline J Springer
Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
Cancer research 2007;67(10):4949-55.
2006: Silke Schepelmann; Caroline J Springer
Viral vectors for gene-directed enzyme prodrug therapy.
Current gene therapy 2006;6(6):647-70.
2006: Astrid Mayer; Roslyn J Francis; Surinder K Sharma; Berend Tolner; Caroline J Springer; Jan Martin; Geoffrey M Boxer; James Bell; Alan J Green; John A Hartley; Clare Cruickshank; Julie Wren; Kerry A Chester; Richard H J Begent
A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6509-16.
2006: Ion Niculescu-Duvaz; Esteban Roman; Steven R Whittaker; Frank Friedlos; Ruth Kirk; Ian Scanlon; Lawrence C Davies; Dan Niculescu-Duvaz; Richard Marais; Caroline J Springer
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Journal of medicinal chemistry 2006;49(1):407-16.
2005: Lawrence C Davies; Frank Friedlos; Douglas Hedley; Jan Martin; Lesley M Ogilvie; Ian Scanlon; Caroline J Springer
Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Journal of medicinal chemistry 2005;48(16):5321-8.
2005: Silke Schepelmann; Paul L Hallenbeck; Lesley M Ogilvie; Douglas Hedley; Frank Friedlos; Janet Martin; Ian Scanlon; Carl Hay; Lynda K Hawkins; Richard Marais; Caroline J Springer
Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
Cancer research 2005;65(12):5003-8.
2005: Ion Niculescu-Duvaz; Caroline J Springer
Introduction to the background, principles, and state of the art in suicide gene therapy.
Molecular biotechnology 2005;30(1):71-88.
2004: Maria Karasarides; Antonio Chiloeches; Robert Hayward; Dan Niculescu-Duvaz; Ian Scanlon; Frank Friedlos; Lesley M Ogilvie; Douglas Hedley; Jan Martin; Christopher J Marshall; Caroline J Springer; Richard Marais
B-RAF is a therapeutic target in melanoma.
Oncogene 2004;23(37):6292-8.
2004: Ion Niculescu-Duvaz; Ian Scanlon; Dan Niculescu-Duvaz; Frank Friedlos; Janet Martin; Richard Marais; Caroline J Springer
Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Journal of medicinal chemistry 2004;47(10):2651-8.
2004: Claudia Wellbrock; Lesley M Ogilvie; Douglas Hedley; Maria Karasarides; Jan Martin; Dan Niculescu-Duvaz; Caroline J Springer; Richard Marais
V599EB-RAF is an oncogene in melanocytes.
Cancer research 2004;64(7):2338-42.
2004: Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Cell 2004;116(6):855-67.
2004: Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Caroline J Springer
Design of prodrugs for suicide gene therapy.
Methods in molecular medicine 2004;90():161-202.
2004: Caroline J Springer
Introduction to vectors for suicide gene therapy.
Methods in molecular medicine 2004;90():29-45.
2004: Ion Niculescu-Duvaz; Caroline J Springer
Introduction to the background, principles, and state of the art in suicide gene therapy.
Methods in molecular medicine 2004;90():1-27.
2003: Ian Scanlon; Panos Lehouritis; Ion Niculescu-Duvaz; Richard Marais; Caroline J Springer
Gene regulation in cancer gene therapy strategies.
Current medicinal chemistry 2003;10(20):2175-84.
2003: Dan Niculescu-Duvaz; James A Heyes; Caroline J Springer
Structure-activity relationship in cationic lipid mediated gene transfection.
Current medicinal chemistry 2003;10(14):1233-61.
2003: Robert Spooner; Frank Friedlos; K Maycroft; Stephen M Stribbling; J Roussel; J Brueggen; B Stolz; Terence O'Reilly; J Wood; A Matter; Richard Marais; Caroline J Springer
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
British journal of cancer 2003;88(10):1622-30.
2003: Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Frank Friedlos; Jan Martin; Panos Lehouritis; Richard Marais; Caroline J Springer
Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Journal of medicinal chemistry 2003;46(9):1690-705.
2002: Frank Friedlos; Lawrence Davies; Ian Scanlon; Lesley M Ogilvie; Janet Martin; Stephen M Stribbling; Robert Spooner; Ion Niculescu-Duvaz; Richard Marais; Caroline J Springer
Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Cancer research 2002;62(6):1724-9.
2002: James A Heyes; Dan Niculescu-Duvaz; Robert G Cooper; Caroline J Springer
Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer.
Journal of medicinal chemistry 2002;45(1):99-114.
2002: David H Kirn; Ion Niculescu-Duvaz; Gunnel Hallden; Caroline J Springer
The emerging fields of suicide gene therapy and virotherapy.
Trends in molecular medicine 2002;8(4 Suppl):S68-73.
2001: Robert Spooner; K A Maycroft; H Paterson; Frank Friedlos; Caroline J Springer; Richard Marais
Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy.
International journal of cancer. Journal international du cancer 2001;93(1):123-30.
2000: Robert Spooner; Janet Martin; Frank Friedlos; Richard Marais; Caroline J Springer
In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
Cancer gene therapy 2000;7(10):1348-56.
2000: Caroline J Springer; Ion Niculescu-Duvaz
Prodrug-activating systems in suicide gene therapy.
The Journal of clinical investigation 2000;105(9):1161-7.
2000: MP Napier; Surinder K Sharma; Caroline J Springer; Kenneth D Bagshawe; Alan J Green; Janet Martin; Stephen M Stribbling; N Cushen; D O'Malley; Richard H J Begent
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):765-72.
2000: Stephen M Stribbling; Frank Friedlos; Janet Martin; Lawrence Davies; Robert Spooner; Richard Marais; Caroline J Springer
Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect.
Human gene therapy 2000;11(2):285-92.
2000: Caroline J Springer; Ion Niculescu-Duvaz
Approaches to gene-directed enzyme prodrug therapy (GDEPT).
Advances in experimental medicine and biology 2000;465():403-9.
1999: Ion Niculescu-Duvaz; Frank Friedlos; Dan Niculescu-Duvaz; Lawrence Davies; Caroline J Springer
Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Anti-cancer drug design 1999;14(6):517-38.
1999: R Barbara Pedley; Surinder K Sharma; Geoffrey M Boxer; Robert Boden; Stephen M Stribbling; Lawrence Davies; Caroline J Springer; Richard H J Begent
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Cancer research 1999;59(16):3998-4003.
1999: Ion Niculescu-Duvaz; R G Cooper; Stephen M Stribbling; James A Heyes; J A Metcalfe; Caroline J Springer
Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Current opinion in molecular therapeutics 1999;1(4):480-6.
1999: Ion Niculescu-Duvaz; Dan Niculescu-Duvaz; Frank Friedlos; Robert Spooner; Janet Martin; Richard Marais; Caroline J Springer
Self-immolative anthracycline prodrugs for suicide gene therapy.
Journal of medicinal chemistry 1999;42(13):2485-9.
1999: CS Mason; Caroline J Springer; R G Cooper; G Superti-Furga; Christopher J Marshall; Richard Marais
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.
The EMBO journal 1999;18(8):2137-48.
1998: Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Frank Friedlos; Janet Martin; Robert Spooner; Lawrence Davies; Richard Marais; Caroline J Springer
Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Journal of medicinal chemistry 1998;41(26):5297-309.
1998: Peter F Searle; SJ Weedon; Iain A McNeish; MG Gilligan; MJ Ford; Frank Friedlos; Caroline J Springer; Lawrence S Young; David J Kerr
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene.
Advances in experimental medicine and biology 1998;451():107-13.
1998: Ion Niculescu-Duvaz; Robert Spooner; Richard Marais; Caroline J Springer
Gene-directed enzyme prodrug therapy.
Bioconjugate chemistry 1998;9(1):4-22.
1997: Richard Marais; Robert Spooner; Stephen M Stribbling; Yvonne Light; Janet Martin; Caroline J Springer
A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.
Nature biotechnology 1997;15(13):1373-7.
1997: Nicola K Green; D J Youngs; J P Neoptolemos; Frank Friedlos; Richard J Knox; Caroline J Springer; Gill M Anlezark; N Paul Michael; RG Melton; MJ Ford; Lawrence S Young; David J Kerr; Peter F Searle
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Cancer gene therapy 1997;4(4):229-38.
1997: Ion Niculescu-Duvaz; Caroline J Springer
Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations.
Expert opinion on investigational drugs 1997;6(6):685-703.
1997: Frank Friedlos; W A Denny; Brian Palmer; Caroline J Springer
Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.
Journal of medicinal chemistry 1997;40(8):1270-5.
1997: J A Bridgewater; R J Knox; J D Pitts; Mary K Collins; Caroline J Springer
The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.
Human gene therapy 1997;8(6):709-17.
1997: Stephen M Stribbling; Janet Martin; R Barbara Pedley; J A Boden; Surinder K Sharma; Caroline J Springer
Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Cancer chemotherapy and pharmacology 1997;40(4):277-84.
1997: Janet Martin; Stephen M Stribbling; G K Poon; Richard H J Begent; MP Napier; Surinder K Sharma; Caroline J Springer
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
Cancer chemotherapy and pharmacology 1997;40(3):189-201.
1996: Caroline J Springer; Vassilios Bavetsias; Ann L Jackman; F Thomas Boyle; D Marshall; R Barbara Pedley; G M Bisset
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Anti-cancer drug design 1996;11(8):625-36.
1996: Richard Marais; Robert Spooner; Yvonne Light; Janet Martin; Caroline J Springer
Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Cancer research 1996;56(20):4735-42.
1996: D C Blakey; P J Burke; D H Davies; R I Dowell; S J East; K P Eckersley; J E Fitton; J McDaid; R G Melton; Ion Niculescu-Duvaz; P E Pinder; S K Sharma; A F Wright; Caroline J Springer
ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Cancer research 1996;56(14):3287-92.
1996: R I Dowell; Caroline J Springer; D H Davies; E M Hadley; P J Burke; F Thomas Boyle; R G Melton; T A Connors; D C Blakey; A B Mauger
New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
Journal of medicinal chemistry 1996;39(5):1100-5.
1995: Caroline J Springer; R Dowell; P J Burke; E Hadley; D H Davis; D C Blakey; R G Melton; Ion Niculescu-Duvaz
Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Journal of medicinal chemistry 1995;38(26):5051-65.
1995: J A Bridgewater; Caroline J Springer; Richard J Knox; Nigel P Minton; N P Michael; Mary K Collins
Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2362-70.
1995: D C Blakey; P J Burke; D H Davies; R I Dowell; R G Melton; Caroline J Springer; A F Wright
Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease.
Biochemical Society transactions 1995;23(4):1047-50.
1995: D C Blakey; D H Davies; R I Dowell; S J East; P J Burke; S K Sharma; Caroline J Springer; A B Mauger; R G Melton
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
British journal of cancer 1995;72(5):1083-8.
1995: Caroline J Springer; Ion Niculescu-Duvaz
Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Anti-cancer drug design 1995;10(5):361-72.
1994: Kenneth D Bagshawe; Surinder K Sharma; Caroline J Springer; G T Rogers
Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(10):879-91.
1994: S A Eccles; W J Court; Gary Box; C J Dean; R G Melton; Caroline J Springer
Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Cancer research 1994;54(19):5171-7.
1994: Caroline J Springer; Ion Niculescu-Duvaz; R Barbara Pedley
Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
Journal of medicinal chemistry 1994;37(15):2361-70.
1994: Surinder K Sharma; Kenneth D Bagshawe; PJ Burke; J A Boden; G T Rogers; Caroline J Springer; R G Melton; R F Sherwood
Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Cancer 1994;73(3 Suppl):1114-20.
1994: Surinder K Sharma; J A Boden; Caroline J Springer; PJ Burke; Kenneth D Bagshawe
Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
Cell biophysics 1994;24-25():219-28.
1994: Caroline J Springer; G K Poon; S K Sharma; Kenneth D Bagshawe
Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Cell biophysics 1994;24-25():193-207.
1993: Caroline J Springer; G K Poon; Surinder K Sharma; Kenneth D Bagshawe
Identification of prodrug, active drug, and metabolites in an ADEPT clinical study.
Cell biophysics 1993;22(1-3):9-26.
1993: D C Blakey; B E Valcaccia; S East; A F Wright; F Thomas Boyle; Caroline J Springer; P J Burke; R G Melton; K D Bagshawe
Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
Cell biophysics 1993;22(1-3):1-8.
1992: A Sunters; Caroline J Springer; Kenneth D Bagshawe; Robert Souhami; John A Hartley
The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid.
Biochemical pharmacology 1992;44(1):59-64.
1991: Caroline J Springer; P Antoniw; Kenneth D Bagshawe; D E Wilman
Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
Anti-cancer drug design 1991;6(5):467-79.
1991: Kenneth D Bagshawe; Surinder K Sharma; Caroline J Springer; P Antoniw; J A Boden; G T Rogers; PJ Burke; R G Melton; R F Sherwood
Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
Disease markers 1991;9(3-4):233-8.
1991: Surinder K Sharma; Kenneth D Bagshawe; Caroline J Springer; PJ Burke; G T Rogers; J A Boden; P Antoniw; R G Melton; R F Sherwood
Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
Disease markers 1991;9(3-4):225-31.
1991: Caroline J Springer; Kenneth D Bagshawe; Surinder K Sharma; F Searle; J A Boden; P Antoniw; PJ Burke; G T Rogers; R F Sherwood; R G Melton
Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
European journal of cancer (Oxford, England : 1990) 1991;27(11):1361-6.
1990: P Antoniw; Caroline J Springer; Kenneth D Bagshawe; F Searle; R G Melton; G T Rogers; PJ Burke; R F Sherwood
Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
British journal of cancer 1990;62(6):909-14.
1990: Caroline J Springer; P Antoniw; Kenneth D Bagshawe; F Searle; G M Bisset; Michael Jarman
Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Journal of medicinal chemistry 1990;33(2):677-81.
1988: Kenneth D Bagshawe; Caroline J Springer; F Searle; P Antoniw; Surinder K Sharma; R G Melton; R F Sherwood
A cytotoxic agent can be generated selectively at cancer sites.
British journal of cancer 1988;58(6):700-3.